SCHEMBL9973593

SCHEMBL9973593

O=Cc1ccc2ncnc(Nc3ccccc3)c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.65
MAPK1 P28482 4/20 0.63
KDM4E B2RXH2 2/20 0.63
HTT P42858 1/20 0.63
CLK4 Q9HAZ1 5/20 0.60
DAPK3 O43293 1/20 0.60
MAP4K4 O95819 1/20 0.60
ABL1 P00519 1/20 0.60
ERBB2 P04626 1/20 0.60
PIM1 P11309 1/20 0.60
PRKACA P17612 1/20 0.60
LTK P29376 1/20 0.60
MAPK8 P45983 1/20 0.60
CSNK1A1 P48729 1/20 0.60
RPS6KA3 P51812 1/20 0.60
LIMK1 P53667 1/20 0.60
MAP2K1 Q02750 1/20 0.60
ACVR1 Q04771 1/20 0.60
TYRO3 Q06418 1/20 0.60
MAP4K2 Q12851 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6957191 0.82 EGFR (0.60) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL3243687 0.81 EGFR (0.59) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL2511768 0.80 EGFR (0.53) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL2884910 0.80 LMNA (0.67) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL2882274 0.79 CYP1A2 (0.50) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL30513 0.79 EGFR (1.00) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL8225745 0.79 KDM4E (0.73) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL29690398 0.79 EGFR (1.00) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL15051337 0.78 BRAF (0.84) EGFRMAPK1KDM4EHTTCLK4
SCHEMBL1192879 0.78 EGFR (0.70) EGFRMAPK1KDM4EHTTCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 EGFR 2/4885MAPK1 140/4885KDM4E 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.